GlycanAge Secures £3.3M Seed Funding for Diagnostic Expansion
GlycanAge, a biotech startup based in London, announced the successful completion of its £3.3 million ($4.2 million) seed funding round on 19th February 2024. The round was led by venture capital fund LAUNCHub Ventures and UK-based deep-tech fund Kadmos Capital. This funding milestone represents a significant step forward in GlycanAge's mission to revolutionize personalized preventative healthcare through the innovative field of glycan biomarkers.
Despite the challenges historically faced by the field of glycobiology due to scientific complexities and lack of necessary technologies, advancements in technology are rapidly changing the landscape.
The company's co-founder and Chief Scientific Officer, Gordan Lauc, and his team have been at the forefront of advancing high throughput glycomic analysis and harnessing glycan biomarkers for precision medicine. GlycanAge aims to leverage these breakthroughs to establish glycomics as a pivotal technology in disease detection, patient stratification, and therapy monitoring.
The newly acquired £3.3 million seed funding will enable GlycanAge to shift its focus from the longevity space to the broader diagnostics market. With the goal of developing disease-specific prognostic biomarkers, the funding will support the company in establishing a clear regulatory strategy and product pipeline. Additionally, the company has received significant grant support to bridge the gap between diagnostics and artificial intelligence. With the support of LAUNCHub Ventures and Kadmos Capital, GlycanAge is poised to continue its journey towards transforming healthcare and empowering individuals to take charge of their well-being.
They've invested in GlycanAge
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK